Cardiotoxicity
Conditions
Brief summary
The aim of the present study is to evaluate the protective impact of cardioprotective medications on the chemotherapy- induced cardiotoxicity.
Detailed description
The goal of this interventional study is to evaluate the protective impact of Angiotensin-converting enzyme (ACE) inhibitors versus β-blockers on the cardiotoxicity profile of pediatric patients with acute leukemia. The impact is measured by evaluation of left ventricular ejection fraction (LVEF) by 2D echocardiography at baseline and at the end of Induction phase (42 days).
Interventions
DRUGACE Inhibitors
0.3 mg/kg/dose every 8 hours orally by either a caregiver or caring nurse.
DRUGβ -Blockers
0.05 mg/kg/dose every 12 hours orally by either a caregiver or caring nurse.
Sponsors
Ain Shams University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Intervention model description
Arm 1 Patients will receive ACEIs oral tablets during Induction Phase by either a caregiver or caring nurse. Arm 2 Patients will receive β-blockers oral tablets during Induction Phase by either a caregiver or caring nurse.
Eligibility
Sex/Gender
ALL
Age
1 Years to 18 Years
Healthy volunteers
No
Inclusion criteria
* Willingness of the legal representative of research participant to participate in the study by giving informed consent. * Ability to take oral medication. * Age 2-18 years at the time of diagnosis.
Exclusion criteria
* Documented allergy to cardioprotective medications
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in Left Ventricular Ejection Fraction (LVEF) | LVEF will be measured at Baseline and at the end of Induction Phase (42 Days) | he LVEF will be measure by 2D Echocardiography at baseline and at the end of Induction Phase (42 Days) |
Countries
Egypt
Contacts
Primary ContactChristen Said
Outcome results
None listed